The Patent Finder

Stemrim Inc.

7 patents currently held · Updated Nov 21, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Genomix Co., Ltd. (to 2018)

0
Ending by 2030
Apr 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 30, 2027
    The maintenance fee for Peptide for Inducing Regeneration of Tissue and Use Thereof (US 10,364,276) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
  • 1 fee due Aug 4, 2027
    The maintenance fee for Peptide for Inducing Regeneration of Tissue and Use Thereof (US 10,550,165) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
  • 1 fee due Oct 30, 2027
    The maintenance fee for Therapeutic Agent for Cardiomyopathy, Old Myocardial Infarction and Chronic Heart Failure (US 11,969,459) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,364,276Peptide for Inducing Regeneration of Tissue and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,550,165Peptide for Inducing Regeneration of Tissue and Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,623,078Novel Method for Treating Cardiac Infarction Using HMGB1 Fragment
In force
 · High confidence
In forceHigh confidence
US 9,688,733Novel Method for Treating Spinal Cord Injury Using HMGB1 Fragment
In force
 · High confidence
In forceHigh confidence
US 11,969,459Therapeutic Agent for Cardiomyopathy, Old Myocardial Infarction and Chronic Heart Failure
In force
 · High confidence
In forceHigh confidence
US 11,298,403Therapeutic Agent for Inflammatory Bowel Disease
In force
 · High confidence
In forceHigh confidence
US 12,421,498Ectodermal Mesenchymal Stem Cells and Method for Producing Same
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 7: 2 patents in force now held by others · 4 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 10 abandoned

Showing 1 to 10 of 16, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
18/776,908Disease Treatment Drug Based on Mesenchymal-Stem-Cell MobilizationJul 18, 2024Pending
18/152,249Pharmaceuticals That Promote Functional Regeneration of Damaged TissuesJan 10, 2023Abandoned
18/069,421Peptide for Inducing Regeneration of Tissue and Use ThereofDec 21, 2022Abandoned
18/697,330Drug for Treating Fatty Liver and Nonalcoholic SteatohepatitisSep 30, 2022Pending
17/517,967Agents for Promoting Tissue Regeneration by Recruiting Bone Marrow Mesenchymal Stem Cells And/Or Pluripotent Stem Cells into BloodNov 3, 2021Abandoned
18/017,149Composition for Use in Treating Dystrophic Epidermolysis BullosaJul 21, 2021Pending
17/919,872Formulation Containing HMGB1 Partial PeptideApr 19, 2021Abandoned
17/995,017Peptide Having Mesenchymal Stem Cell Mobilizing ActivityApr 2, 2021Pending
17/631,072Composition for Promoting Growth or Suppressing Decrease of Mesenchymal Stem CellsJul 30, 2020Abandoned
16/713,202Peptide for Inducing Regeneration of Tissue and Use ThereofDec 13, 2019Abandoned
10 of 16 applications shown.
Pro members see all 16 published applications.
Pro members: see all 16 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited